AIVITA Biomedical Publishes Review of GM-CSF History and Rationale as Vaccine Adjuvant in Melanoma Management
IRVINE, Calif., Aug. 3, 2020 /PRNewswire/ — AIVITA Biomedical, Inc., a private biotechnology company developing personalized vaccines for the treatment of cancer and prevention of COVID-19, announced today the publication of the paper, “An update on GM-CSF and its potential role in melanoma management,” in the journal Melanoma Management. Robert O. Dillman, M.D., chief medical officer at … Continued